International Clinical Trial: A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07536308) titled 'A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults' on April 10.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Prevention. Masking: None (Open Label).

Primary Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Condition: COVID-19

Intervention: Biological: OCU500

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: April 29, 2026

Target Sample Size: 80

Countries of Recrui...